Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2233-2235 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 67 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2006 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. / Jankovic, J.; Hunter, C.; Dolimbek, B. Z.; Dolimbek, G. S.; Adler, C. H.; Brashear, A.; Comella, C. L.; Gordon, M.; Riley, D. E.; Sethi, Kapil Dev; Singer, C.; Stacy, M.; Tarsy, D.; Atassi, M. Z.
In: Neurology, Vol. 67, No. 12, 01.12.2006, p. 2233-2235.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
AU - Jankovic, J.
AU - Hunter, C.
AU - Dolimbek, B. Z.
AU - Dolimbek, G. S.
AU - Adler, C. H.
AU - Brashear, A.
AU - Comella, C. L.
AU - Gordon, M.
AU - Riley, D. E.
AU - Sethi, Kapil Dev
AU - Singer, C.
AU - Stacy, M.
AU - Tarsy, D.
AU - Atassi, M. Z.
PY - 2006/12/1
Y1 - 2006/12/1
N2 - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
AB - In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
UR - http://www.scopus.com/inward/record.url?scp=33845939760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845939760&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000249308.66959.43
DO - 10.1212/01.wnl.0000249308.66959.43
M3 - Article
VL - 67
SP - 2233
EP - 2235
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 12
ER -